ISPOR

Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
Abstract, EASL, Therapy, NASH, NAS, ISPOR, Obeticholic acid, NDA, Research, Non-alcoholic fatty liver disease, Meta-analysis, Different, Literature review, Breakthrough therapy, Evidence, Patient, Term Asset-Backed Securities Loan Facility, Institute for Clinical and Economic Review, Fibrosis, NHANES, Prevalence, ICER, Liver, Fatty liver disease, Loan, FDA, Epidemiology, Three Months, Treatment, Cirrhosis, Pharmaceutical industry, Medical imaging, Dietary supplement, Inflammation, Madrigal, Lipid

Multiple resmetirom abstracts accepted for presentation at EASL, including primary results and additional data from the Phase 3 MAESTRO-NASH trial

Key Points: 
  • Multiple resmetirom abstracts accepted for presentation at EASL, including primary results and additional data from the Phase 3 MAESTRO-NASH trial
    CONSHOHOCKEN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of corporate updates and reports first quarter 2023 financial results.
  • Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “In the first quarter of 2023, the Madrigal team made significant progress advancing our regulatory preparations, disease education initiatives, and market access strategy.
  • Additionally, we continue to execute against our clinical development objectives, and have completed enrollment of the MAESTRO-NASH trial.
  • Interest expense for the three month period ended March 31, 2023 was $2.3 million, compared to $0.0 million in the comparable prior year period.

Komodo Health Platform Powers 17 Cutting-Edge Health Economics and Outcomes Research Presentations at ISPOR 2023

Retrieved on: 
Monday, May 8, 2023
Software, Research, Professional Services, Pharmaceutical, Data Management, Venture Capital, Technology, Hospitals, Artificial Intelligence, Health Technology, Science, Health, Komodo, Duke University, Depression, ISPOR, COVID-19, Haemophilia, Genomics, Multiple sclerosis, Pharmacoeconomics, DSM-IV codes, Patient, Novo Nordisk, Janssen Pharmaceuticals, Mab, RWE, Government, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, International Society, Food, Prostate cancer, Pharmaceutical industry, Medical imaging

Komodo Health today announced that its real-world evidence (RWE) technology platform has been used to support 17 new health economics and outcomes research (HEOR) studies being presented at the 2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference.

Key Points: 
  • Komodo Health today announced that its real-world evidence (RWE) technology platform has been used to support 17 new health economics and outcomes research (HEOR) studies being presented at the 2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference.
  • Together, researchers representing Komodo Health, its customers, and its partners will present the results of research analyzing clinical and economic value across a wide range of therapeutic areas, including COVID-19, multiple sclerosis, prostate cancer, and more.
  • “The world’s top Life Sciences research teams are increasingly turning to Komodo’s Healthcare Map and real-world evidence applications to power their research strategies,” said Usha Periyanayagam, Head of Research and Analytics at Komodo Health.
  • Within the Komodo platform, users can perform comprehensive analytics, develop predictive models, and employ custom workflows to unlock a range of patient-centric insights.

Cognito Therapeutics Announces Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting

Retrieved on: 
Monday, May 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mental toughness, Partnership, Cognito, Health policy, ISPE, ISPOR, Deficit spending, Research, Pharmacoeconomics, MCI, CNS, Aetion, Patient, Risk, Amnesia, Diagnosis, AD, Therapy, Summit, International Society for Pharmacoepidemiology, International Society, Disease, Pharmaceutical industry

Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting, held May 7-10 in Boston, MA.

Key Points: 
  • Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting, held May 7-10 in Boston, MA.
  • The Summit is co-located with and being held immediately prior to the Society’s annual international conference, ISPOR 2023 .
  • The Summit is a collaboration between ISPOR, the International Society for Pharmacoepidemiology (ISPE), and the Duke-Margolis Center for Health Policy.
  • ISPOR is a leading professional society for health economics and outcomes research.

Aetion® Launches New Application for Descriptive Analytics and Fast, Reliable Insights

Retrieved on: 
Monday, May 8, 2023
Science, Compatibility, Balance sheet, ISPOR, Tourism, Pharmaceutical industry, Aetion

NEW YORK, May 8, 2023 /PRNewswire/ -- Aetion®, the global leader in real-world evidence technology and analytics, today announced the launch of Aetion® Discover, a new application for exploratory analysis. The application provides users with an intuitive interface to generate swift hypotheses and insights across the biopharmaceutical and medtech lifecycle. As with Aetion® Substantiate — also built on Aetion Evidence Platform® — Discover powers results that are rapid, reliable, and scalable.

Key Points: 
  • NEW YORK, May 8, 2023 /PRNewswire/ -- Aetion®, the global leader in real-world evidence technology and analytics, today announced the launch of Aetion® Discover, a new application for exploratory analysis.
  • The application provides users with an intuitive interface to generate swift hypotheses and insights across the biopharmaceutical and medtech lifecycle.
  • As with Aetion® Substantiate — also built on Aetion Evidence Platform® — Discover powers results that are rapid, reliable, and scalable.
  • Discover is fully compatible with Substantiate, Aetion's application for regulatory-grade descriptive and causal analyses.

Aetion® Launches New Application for Descriptive Analytics and Fast, Reliable Insights

Retrieved on: 
Monday, May 8, 2023
Science, Compatibility, Balance sheet, ISPOR, Tourism, Pharmaceutical industry, Aetion

NEW YORK, May 8, 2023 /PRNewswire/ -- Aetion®, the global leader in real-world evidence technology and analytics, today announced the launch of Aetion® Discover, a new application for exploratory analysis. The application provides users with an intuitive interface to generate swift hypotheses and insights across the biopharmaceutical and medtech lifecycle. As with Aetion® Substantiate — also built on Aetion Evidence Platform® — Discover powers results that are rapid, reliable, and scalable.

Key Points: 
  • NEW YORK, May 8, 2023 /PRNewswire/ -- Aetion®, the global leader in real-world evidence technology and analytics, today announced the launch of Aetion® Discover, a new application for exploratory analysis.
  • The application provides users with an intuitive interface to generate swift hypotheses and insights across the biopharmaceutical and medtech lifecycle.
  • As with Aetion® Substantiate — also built on Aetion Evidence Platform® — Discover powers results that are rapid, reliable, and scalable.
  • Discover is fully compatible with Substantiate, Aetion's application for regulatory-grade descriptive and causal analyses.

Zambon Announces New Data Highlighting Lifetime Burden of Illness in U.S. Patients with Bronchiolitis Obliterans Syndrome at ISPOR 2023

Retrieved on: 
Monday, May 8, 2023
Bronchiolitis, Drug utilization review, SLT, ISPOR, BOS, DLT, CMO, Life expectancy, HSCT, Pharmacoeconomics, Lung transplantation, HIV disease progression rates, Patient, Disease, Health, Hematopoietic stem cell transplantation, Pharmaceutical industry, Zambon

The study included adult BOS patients receiving a HSCT (rapid decliners), HSCT (gradual decliners), single lung transplant (SLT) or double lung transplant (DLT).

Key Points: 
  • The study included adult BOS patients receiving a HSCT (rapid decliners), HSCT (gradual decliners), single lung transplant (SLT) or double lung transplant (DLT).
  • The study showed that BOS patients have significant morbidity leading to reduced life expectancy and high direct medical expenses.
  • The average lifetime cost of BOS patients was $83,500 ranging from $27,900 to $96,900 across all sub-types.
  • Details about the 2023 ISPOR Meeting presentation are as follows:
    For more information on ISPOR's program, please visit the conference website at https://www.ispor.org/conferences-education/conferences/upcoming-confere...

Next-Generation eCOA/ePRO Provider uMotif Welcomes SAFIRA Clinical Research Co-founder and Clinical Trial Technology Innovator Willie Muehlhausen as Scientific Advisor

Retrieved on: 
Monday, May 8, 2023
Industry Dive, Clinical data management, American Opportunity Tax Credit, ISPOR, Clinical trial, ICON, Innovation, Research, Phenome-wide association study, Organization, Motif, Patient, Poster, BYOD, ChromeOS, Migration, Pharmaceutical industry, Medical imaging

BOSTON, May 8, 2023 /PRNewswire-PRWeb/ -- uMotif – one of the clinical trial technology market's fastest growing companies – reiterated its status as the pacesetter in next-generation eCOA/ePRO by welcoming SAFIRA Clinical Research Co-founder and international eClinical technology expert Willie Muehlhausen as a Scientific Advisor.

Key Points: 
  • uMotif CEO Steve Rosenberg ( LinkedIn ) said, "We're delighted to welcome Willie Muehllhausen to uMotif as a Scientific Advisor.
  • He co-founded SAFIRA Clinical Research in 2021 to offer services to decentralized clinical trial technology vendors, sponsors and CROs.
  • SAFIRA Clinical Research has become the go-to organization for providing unbiased, independent, scientific technology and product evaluations.
  • Prior to SAFIRA Clinical Research, Muehlhausen was Founder and Managing Director of Muehlhausen Ltd, where he advised sponsors, vendors, investment companies and researchers on digitization strategies for remote and virtual clinical trials.

uMotif and Veramed Partner to Offer Advanced Biostatistical Data Analysis, Visualization Combined with Industry-Leading Patient eCOA/ePRO Data Capture and Analytics

Retrieved on: 
Monday, May 8, 2023
Partnership, ISPOR, Clinical trial, Meta-analysis, Parkinson's disease, Data analysis, Patient, Biostatistics, Geography, Pharmaceutical industry, Veram semper et solidam

BOSTON, May 8, 2023 /PRNewswire-PRWeb/ -- uMotif – one of the clinical trial technology market's fastest growing companies – continues to redefine how eCOA/ePRO data is collected, reported, visualized and analyzed with the announcement of a strategic partnership with advanced biostatistics consultancy Veramed.

Key Points: 
  • The highly-scalable uMotif eCOA/ePRO platform combines the industry's most innovative eCOA/ePRO technology with an unmatched focus on true patient centricity.
  • The modern platform consistently achieves greater than 90 percent compliance, generating double the expected volume of data in real-world studies.
  • Together, uMotif and Veramed generate high quality, actionable insights to drive quantifiable improvements in clinical research.
  • Through the partnership with Veramed, sponsors get the unique advantages of the industry's most advanced data analysis and visualization support on top of uMotif's market-leading platform for ePRO/eCOA data capture, reporting, and analytics.

Research to Be Presented at ISPOR 2023 Illuminates the Economic Costs of Melanoma and Non-Small Cell Lung Cancer and Provides Insights That Can Help Strengthen the Quality and Approach to Real-World Evidence Generation

Retrieved on: 
Friday, May 5, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Partnership, Drug development, Professional, ISPOR, McKesson Corporation, Cancer, MBA, RWD, Lung cancer, Electronic health record, Doctor of Philosophy, CDS, Association of American Cancer Institutes, MD, EHR, Patient, Melanoma, RWE, Metastasis, Continuum, Disease, Medical imaging, Nursing, Medical device, NSCLC

“It’s an unprecedented time for patients living with cancer as life sciences companies race to create and expand access to new cutting-edge targeted therapies.

Key Points: 
  • “It’s an unprecedented time for patients living with cancer as life sciences companies race to create and expand access to new cutting-edge targeted therapies.
  • With this level of innovation comes increased complexity and cost for manufacturers, providers, and patients,” said Susan Shiff, PhD, MBA, president, Ontada.
  • “Ontada’s work continues to support science in oncology and improve cancer care through our real-world data and research.
  • The study concludes that CDS tools can have a significant impact on assisting providers in identifying precision oncology treatment options.

CENTOGENE to Participate in Upcoming Conferences in May

Retrieved on: 
Friday, May 5, 2023
Human genome, ISPOR, Personalized medicine, Diagnosis, RNA, Boston Convention and Exhibition Center, Convention center, WODC, Therapy, Hotel, Online shopping, Pharma

and ROSTOCK, Germany and BERLIN, May 05, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for May 2023.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, May 05, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for May 2023.
  • CENTOGENE representatives are attending events in Brazil, the U.S., and Germany, as well as virtually, and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities.
  • Location: Boston Convention and Exhibition Center, Boston, U.S.
    To learn more about the ISPOR 2023 conference and set up an in-person meeting with the CENTOGENE team, please visit the event webpage ( https://link.centogene.com/3LAupSu ).
  • Location: Gaylord National Resort and Convention Center, Washington, D.C., U.S.
    To learn more about WODC 2023 and set up an in-person meeting with the CENTOGENE team, please visit the event webpage ( https://link.centogene.com/3AXOg9m ).